ReviewTrends in molecular medicine2008
The moonlighting enzyme CD13: old and new functions to target.
Review in Trends in molecular medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 211 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
211 citing papers in PubMed, 404 citations in OpenAlex.
- First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.Investigational new drugs · 2015Trial
- MAP2-mediated integrin dysregulation reprograms cancer cell plasticity in hepatocellular carcinoma.Nature communications · 2026Article
- The Probiotic Strain Hafnia Alvei HA4597 and Its Protein Extract Selectively Activate Membrane Digestive Enzymes of Intestinal Cells in Mice.Life (Basel, Switzerland) · 2026Article
- CRISPR/Cas9 loss-of-function screen in a neuronal model of AP-4 deficiency identifies ATG9A trafficking modulators.JCI insight · 2026Article
- Harnessing tumor-associated exosomal aminopeptidase N as a dual-function tool for monitoring and tackling chemoresistance in gastric cancer.Cell communication and signaling : CCS · 2026Article
- Oral peptide drug delivery: design of SEDDS providing a protective effect against intestinal membrane-bound enzymes.Drug delivery and translational research · 2026Article
- Basal gland localization and focal distribution of OLFM4-expressing cells in increasing severity of gastric intestinal metaplasia.bioRxiv : the preprint server for biology · 2026Article
- Cell entry mechanisms of porcine enteric coronaviruses.The Journal of biological chemistry · 2026Review
- CD13 is a bona-fide marker of bovine pre-adipocytes with potential in cultivated fat applications.NPJ science of food · 2026Article
- Identification of core genes and transcription factors related to metabolic reprogramming in atherosclerosis: a multi-omics analysis and experimental validation approach.Frontiers in molecular biosciences · 2026Article
- Dual nanobody-redirected and Bi-specific CD13/TIM3 CAR T cells eliminate AML xenografts without toxicity to human HSCs.Oncoimmunology · 2025Article
- Proteomic Study Revealed a Distinction Between Human Dermal Fibroblasts and Mesenchymal Stem Cells from Different Sources.Stem cell reviews and reports · 2025Article
- Non-Pancreatic Digestive Enzymes.Biomolecules · 2025Review
- CD45 and Basigin (CD147) Are Functional Ligands for Galectin-8 on Human Leukocytes.Biomolecules · 2025Article
- Identification of novel biomarkers involved in oral squamous cell carcinoma by whole transcriptome sequencing and bioinformatics analysis.Cancer cell international · 2025Article
- Review
- CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [European journal of nuclear medicine and molecular imaging · 2025Article
- Opiorphin and neuropathic pain: a promising treatment approach?Inflammopharmacology · 2025Review
- Early evaluation of anti-angiogenic effects with gadolinium(III) labeled APN/CD13 specific binding peptides magnetic resonance imaging.Scientific reports · 2025Article
- Transcriptome analysis reveals no obvious unintended effects in the spleen of CRISPR/Cas9-mediated CD163 and pAPN double-knockout pigs.Functional & integrative genomics · 2025Article
151 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aminopeptidase N (CD13) is a widely expressed ectoenzyme with functions that do not always depend on its enzymatic activity: an aspect that has been overlooked. Numerous CD13-targeting tools have been developed in the last few years. Several of them are already undergoing clinical trials, and there are promising reports on the effectiveness of others in animal models of disease. However, their efficacy might be obscured by their effects on unrecognized functions of CD13, resulting in unexpected complications. The purpose of this review is (i) to discuss the various functions ascribed to CD13 and the possible mechanisms behind them and (ii) to consider some of the questions that need to be answered to achieve a better understanding of the biological relevance of these functions, a more precise interpretation of the results obtained after their manipulation and a more rational design of CD13-targeting agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.